Viewing Study NCT00870805


Ignite Creation Date: 2025-12-25 @ 3:22 AM
Ignite Modification Date: 2026-01-05 @ 11:34 PM
Study NCT ID: NCT00870805
Status: COMPLETED
Last Update Posted: 2013-02-27
First Post: 2009-03-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Ultrabrief Pulsewidth Electroconvulsive Therapy (ECT)
Sponsor: The University of New South Wales
Organization:

Study Overview

Official Title: A Controlled Study of Ultrabrief Pulsewidth ECT (Electroconvulsive Therapy)
Status: COMPLETED
Status Verified Date: 2011-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: UB ECT
Brief Summary: Electroconvulsive Therapy (ECT) remains essential to contemporary psychiatric practice and is one of the safest and most effective treatments available for depression. Despite modern advances in pharmacotherapy, about 15-20 per cent of all hospitalised patients receive treatment with ECT. Its use, however, is limited by concerns over associated cognitive side effects.

Recent research has suggested that using an ultrabrief pulsewidth with ECT may greatly reduce cognitive side effects, while maintaining efficacy (Sackeim et al 2008). Preliminary results were positive for unilateral ECT, however, suggest that for bilateral ECT, dosing may need to be adjusted to preserve efficacy while reducing side effects. This study will examine the relative cognitive side effects and efficacy of right unilateral and bilateral ECT given with a standard pulsewidth or an ultrabrief pulsewidth. Some participants will also receive an MRI scan before and after ECT.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: